International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study
International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study
复制标题
DOI：
10.1016/s1470-2045(14)71222-7
复制
发表时间：
2015-03-01
期刊：
影响因子：
51.1
通讯作者：
Heng, Daniel Y. C.
中科院分区：
文献类型：
--
作者：
Ko, Jenny J.;Xie, Wanling;Heng, Daniel Y. C.
背景以前的转移性肾细胞癌患者二线系统治疗的预后模型尚未在靶向治疗的背景下进行研究。我们试图验证国际转移性肾细胞癌数据库联盟（IMDC）模型在一线靶向治疗进展后接受下一线靶向治疗的转移性肾细胞癌患者中的应用。方法在这项基于人群的研究中，我们分析了在加拿大、美国、希腊、日本、新加坡、韩国、日本、美国、日本、韩国、美国、日本、日本、美国、日本、日本、美国、美国、日本、美国、美国、日本、美国、日本、美国、和丹麦。主要终点是自二线治疗开始以来的总生存期。我们比较了IMDC模型的预后性能与三因素MSKCC模型用于以前治疗的患者的总生存率，因为开始的二线靶向therapeutic.Findings在2005年1月1日和2012年11月30日之间，我们纳入了1021例接受二线靶向治疗的患者。自二线靶向治疗开始以来的中位总生存期为12.5个月（95% CI 11.3-14.3）。IMDC模型中6个预定义因素中的5个（贫血、血小板增多、嗜中性粒细胞增多、Karnofsky体能状态[KPS]）
Background Previous prognostic models for second-line systemic therapy in patients with metastatic renal cell carcinoma have not been studied in the setting of targeted therapy. We sought to validate the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model in patients with metastatic renal cell carcinoma receiving next-line targeted therapy after progression on first-line targeted therapy.Methods In this population-based study, we analysed patients who received second-line targeted therapy for metastatic renal cell carcinoma at 19 centres in Canada, USA, Greece, Japan, Singapore, South Korea, and Denmark. The primary endpoint was overall survival since the initiation of second-line therapy. We compared the prognostic performance of the IMDC model with the three-factor MSKCC model used for previously treated patients for overall survival since the start of second-line targeted therapy.Findings Between Jan 1, 2005, and Nov 30, 2012, we included 1021 patients treated with second-line targeted therapy. Median overall survival since the start of second-line targeted therapy was 12.5 months (95% CI 11.3-14.3). Five of six predefined factors in the IMDC model (anaemia, thrombocytosis, neutrophilia, Karnofsky performance status [KPS]